Switch theme
Sign up to access all valuation multiples
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
2015
n/a
LTM Revenue $48.6M
LTM EBITDA $6.4M
$35.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EZZ Life Science has a last 12-month revenue (LTM) of $48.6M and a last 12-month EBITDA of $6.4M.
In the most recent fiscal year, EZZ Life Science achieved revenue of $42.7M and an EBITDA of $6.7M.
EZZ Life Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EZZ Life Science valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.6M | XXX | $42.7M | XXX | XXX | XXX |
| Gross Profit | $48.6M | XXX | $32.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | $6.4M | XXX | $6.7M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $6.1M | XXX | $6.2M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $4.4M | XXX | $4.5M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, EZZ Life Science's stock price is AUD 2 (or $1).
EZZ Life Science has current market cap of AUD 73.8M (or $47.4M), and EV of AUD 54.4M (or $35.0M).
See EZZ Life Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $35.0M | $47.4M | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, EZZ Life Science has market cap of $47.4M and EV of $35.0M.
EZZ Life Science's trades at 0.8x EV/Revenue multiple, and 5.3x EV/EBITDA.
Equity research analysts estimate EZZ Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EZZ Life Science has a P/E ratio of 10.8x.
See valuation multiples for EZZ Life Science and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47.4M | XXX | $47.4M | XXX | XXX | XXX |
| EV (current) | $35.0M | XXX | $35.0M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.4x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBIT | 5.7x | XXX | 5.7x | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.8x | XXX | 10.7x | XXX | XXX | XXX |
| EV/FCF | 7.8x | XXX | 8.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEZZ Life Science's last 12 month revenue growth is 24%
EZZ Life Science's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
EZZ Life Science's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EZZ Life Science's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for EZZ Life Science and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EZZ Life Science acquired XXX companies to date.
Last acquisition by EZZ Life Science was XXXXXXXX, XXXXX XXXXX XXXXXX . EZZ Life Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was EZZ Life Science founded? | EZZ Life Science was founded in 2015. |
| Where is EZZ Life Science headquartered? | EZZ Life Science is headquartered in Australia. |
| Is EZZ Life Science publicy listed? | Yes, EZZ Life Science is a public company listed on ASX. |
| What is the stock symbol of EZZ Life Science? | EZZ Life Science trades under EZZ ticker. |
| When did EZZ Life Science go public? | EZZ Life Science went public in 2021. |
| Who are competitors of EZZ Life Science? | Similar companies to EZZ Life Science include e.g. Epigenomics, ToolGen, 4basebio, Genus. |
| What is the current market cap of EZZ Life Science? | EZZ Life Science's current market cap is $47.4M |
| What is the current revenue of EZZ Life Science? | EZZ Life Science's last 12 months revenue is $48.6M. |
| What is the current revenue growth of EZZ Life Science? | EZZ Life Science revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of EZZ Life Science? | Current revenue multiple of EZZ Life Science is 0.7x. |
| Is EZZ Life Science profitable? | Yes, EZZ Life Science is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EZZ Life Science? | EZZ Life Science's last 12 months EBITDA is $6.4M. |
| What is EZZ Life Science's EBITDA margin? | EZZ Life Science's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of EZZ Life Science? | Current EBITDA multiple of EZZ Life Science is 5.4x. |
| What is the current FCF of EZZ Life Science? | EZZ Life Science's last 12 months FCF is $4.5M. |
| What is EZZ Life Science's FCF margin? | EZZ Life Science's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of EZZ Life Science? | Current FCF multiple of EZZ Life Science is 7.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
